



Gastric/GEJ Adenocarcinoma: Key Journal Articles and Abstracts

[Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol.* 2018;4\(5\):e180013.](#)

[Fuchs CS, Tomasek J, Yong CJ, et al; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma \(REGARD\): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet.* 2014;383\(9911\):31-39.](#)

[Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. *J Clin Oncol.* 2019;37\(4 suppl\):Abstract 2.](#)

[Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer \(TAGS\): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2018;19\(11\):1437-1448.](#)

[Shitara K, Özgüroğlu M, Bang YJ, et al; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer \(KEYNOTE-061\): a randomised, open-label, controlled, phase 3 trial. *Lancet.* 2018;392\(10142\):123-133.](#)

[Taberero J, Van Cutsem E, Bang YJ, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction \(G/GEJ\) adenocarcinoma: the phase III KEYNOTE-062 study. *J Clin Oncol.* 2019;37:Abstract LBA4007.](#)

[Wilke H, Muro K, Van Cutsem E, et al; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma \(RAINBOW\): a double-blind, randomised phase 3 trial. *Lancet Oncol.* 2014;15\(11\):1224-1235.](#)